Vanguard Group
EVOK

Vanguard Group’s Evoke Pharma EVOK Stock Holding History

Vanguard Group’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,759
Closed -$93.2K – 4353
2025
Q3 		$93.2K Buy
+18,759
New +$93.1K ﹤0.01% 4234
2024
Q3 		– Sell
-2,488
Closed -$15.8K – 4355
2024
Q2 		$15.8K Hold
2,488
– – ﹤0.01% 4371
2024
Q1 		$18.2K Hold
2,488
– – ﹤0.01% 4397
2023
Q4 		$31.4K Hold
2,488
– – ﹤0.01% 4413
2023
Q3 		$41.2K Hold
2,488
– – ﹤0.01% 4435
2023
Q2 		$49.3K Hold
2,488
– – ﹤0.01% 4458
2023
Q1 		$56.7K Hold
2,488
– – ﹤0.01% 4460
2022
Q4 		$80K Hold
2,488
– – ﹤0.01% 4413
2022
Q3 		$56K Sell
2,488
-123
-5% -$4.04K ﹤0.01% 4538
2022
Q2 		$102K Sell
2,611
-5,144
-66% -$245K ﹤0.01% 4547
2022
Q1 		$553K Sell
7,755
-55
-0.7% -$4.38K ﹤0.01% 4379
2021
Q4 		$618K Hold
7,810
– – ﹤0.01% 4387
2021
Q3 		$1.46M Buy
7,810
+31
+0.4% +$5.23K ﹤0.01% 4155
2021
Q2 		$1.53M Sell
7,779
-120
-2% -$25.7K ﹤0.01% 4044
2021
Q1 		$2.08M Buy
7,899
+746
+10% +$299K ﹤0.01% 3854
2020
Q4 		$2.66M Sell
7,153
-26
-0.4% -$13.4K ﹤0.01% 3586
2020
Q3 		$4.85M Buy
7,179
+2,617
+57% +$1.67M ﹤0.01% 3168
2020
Q2 		$2.33M Buy
4,562
+1,212
+36% +$337K ﹤0.01% 3391
2020
Q1 		$560K Hold
3,350
– – ﹤0.01% 3647
2019
Q4 		$782K Hold
3,350
– – ﹤0.01% 3692
2019
Q3 		$415K Buy
3,350
+1,789
+115% +$240K ﹤0.01% 3854
2019
Q2 		$140K Sell
1,561
-2,856
-65% -$283K ﹤0.01% 4020
2019
Q1 		$954K Buy
4,417
+667
+18% +$228K ﹤0.01% 3635
2018
Q4 		$1.34M Buy
3,750
+24
+0.6% +$8.88K ﹤0.01% 3478
2018
Q3 		$1.6M Hold
3,726
– – ﹤0.01% 3600
2018
Q2 		$1.34M Buy
3,726
+213
+6% +$79.8K ﹤0.01% 3611
2018
Q1 		$1.05M Sell
3,513
-12
-0.3% -$3.95K ﹤0.01% 3638
2017
Q4 		$1.15M Sell
3,525
-111
-3% -$46K ﹤0.01% 3579
2017
Q3 		$1.75M Hold
3,636
– – ﹤0.01% 3441
2017
Q2 		$1.34M Buy
3,636
+476
+15% +$182K ﹤0.01% 3504
2017
Q1 		$1.41M Buy
3,160
+1,626
+106% +$666K ﹤0.01% 3489
2016
Q4 		$447K Buy
1,534
+53
+4% +$13.7K ﹤0.01% 3755
2016
Q3 		$482K Buy
1,481
+1,048
+242% +$480K ﹤0.01% 3763
2016
Q2 		$427K Buy
433
+20
+5% +$15.7K ﹤0.01% 3819
2016
Q1 		$302K Buy
413
+2
+0.5% +$1.02K ﹤0.01% 3886
2015
Q4 		$195K Hold
411
– – ﹤0.01% 4019
2015
Q3 		$175K Buy
411
+34
+9% +$21.4K ﹤0.01% 4039
2015
Q2 		$283K Buy
377
+20
+6% +$17K ﹤0.01% 3983
2015
Q1 		$360K Buy
357
+19
+6% +$17.1K ﹤0.01% 3902
2014
Q4 		$287K Hold
338
– – ﹤0.01% 3841
2014
Q3 		$267K Buy
338
+2
+0.6% +$1.93K ﹤0.01% 3849
2014
Q2 		$378K Buy
336
+7
+2% +$8.04K ﹤0.01% 3743
2014
Q1 		$395K Buy
329
+77
+31% +$110K ﹤0.01% 3705
2013
Q4 		$270K Buy
+252
New +$361K ﹤0.01% 3720

Vanguard Group's EVOK Position: Q4 2025 in Review

Vanguard Group sold out of Evoke Pharma (EVOK) in Q4 2025, closing a stake of 18,759 shares — an estimated $93.2K sold.

Vanguard Group first reported a position in EVOK in Q4 2013 and held it in 44 quarters. The position peaked at $4.85M in Q3 2020. 0 funds tracked by Wall St. Rank hold EVOK as of Q4 2025.

  • Vanguard Group reported no remaining Evoke Pharma position as of Q4 2025 after selling out during the quarter.
  • Vanguard Group sold 18,759 Evoke Pharma shares in Q4 2025, an estimated $93.2K.
  • Vanguard Group first reported a position in Evoke Pharma in Q4 2013 and held it in 44 quarters.
  • Vanguard Group's Evoke Pharma position peaked at $4.85M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.